Interleukin 6 and interferon-γ gene expression in lung transplant recipients with refractory acute cellular rejection: Implications for monitoring and inhibitory by treatment with aerosolized cyclosporine

Transplantation

Volumn 64, Issue 2, 1997, Pages 263-269

  Iacono, A ^a,b   Dauber, J ^a   Keenan, R ^b   Spichty, K ^a   Cai, J ^a   Grgurich, W ^a   Burckart, G ^c   Smaldone, G ^d   Pham, S ^b   Ohori, N P ^a   Yousem, S ^a   Williams, P ^a   Griffith, B ^b   Zeevi, A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; METHYLPREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE DISEASE; ADOLESCENT; ADULT; AEROSOL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GRAFT FAILURE; GRAFT REJECTION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG LAVAGE; LUNG TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AEROSOLS; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; CYCLOSPORINE; FEMALE; GENE EXPRESSION; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; RNA, MESSENGER; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030860863     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707270-00015     Document Type: Article

References (34)

1. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
2. Trulock EP. Management of lung transplant rejection. Chest 1993; 103: 1566.
3. Griffith BP, Hardesty RL, Armitage JM, et al. Acute rejection of lung allografts with various immunosuppressive protocols. Ann Thorac Surg 12992; 54: 846.
4. Paradis IL, Yousem SA, Griffith BP. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clin Chest Med 1993; 14: 751.
5. Kesten S, Maidenberg A, Winton T, Maurer J. Treatment of presumed and proved acute rejection following six months of lung transplant survival. Am J Respir Crit Care Med 1995; 152: 1321.
6. Halloran S, Battukt T, Goes N. An overview of the cytokines in transplantation. Transplant Sci 1993; 3: 69.
7. Krams SM, Falco DA, Villaneuva JC, et al. Cytokine and T cell receptor gene expression at the site of allograft rejection. Transplantation 1992; 5: 151.
8. Lipman ML, Stevens AC, Bleackley RC, et al. The strong correlation of cytotoxic T lymphocyte specific serine protease gene transcripts with renal allograft rejection. Transplantation 1993; 53: 73.
9. Martinez OM, Krams S, Sterneck M, et al. Intragraft cytokine profile during human liver allograft rejection. Transplantation 1992; 53: 449.
10. Cunningham DA, Dunn MJ, Yacoub MM, Rose ML. Local production of cytokines in the human cardiac allograft: a sequential study. Transplantation 1994; 57: 1333.
11. Baan CC, Van Emmerik NEEM, Balk AH, et al. Cytokine mRNA expression in endomyocardial biopsies during acute rejection from human heart transplants. Clin Exp Immunol 1994; 97(2): 293.
12. Whitehead BF, Stoehr C, Wu JC, et al. Cytokine gene expression in human lung transplant recipients. Transplantation 1993; 56: 956.
13. Sundaresan S, Alevy YG, Steward N, et al. Cytokine gene transcripts for tumor necrosis factor-a, interleukin-2, and interferon-γ in human pulmonary allografts. J Heart Lung Transplant 1995; 14: 512.
14. Zlotnik A, Moore KW. Interleukin-10. Cytokine 1991; 3: 336.
15. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen presenting cell to inhibit cytokine production by TH1 cells. J Immunol 1991; 146: 3444.
16. de Waal Malefyt R, Haanen J, Spits M, et al. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915.
17. O'Riordan TG, Iacono AT, Keenan RJ, et al. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am J Respir Crit Care Med 1995; 151: 516.
18. Iacono AT, Keenan RJ, Duncan SR, et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med 1996; 153: 1451.
19. Keenan RJ, Zeevi A, Iacono AT, et al. Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics. Surgery 1995; 118: 385.
20. Yousem SA, Berry GJ, Brunt EM, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: lung rejection study group. J Heart Lung Transplant 1990; 12: 713.
21. Gryzan S, Paradis IL, Zeevi A, et al. Unexpectedly high incidence of Pneumocystis carinii infection following heart-lung transplantation. Am Rev Respir Dis 1988; 137: 1268.
22. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294.
23. Brenner CA, Tam AW, Nelson PA. Message amplification phenotyping (MAPPing): a technique to simultaneously measure multiple mRNAs from small numbers of cells. BioTechniques 1989; 7: 1096.
24. Iacono AT, Smaldone GC, Keenan RJ, et al. Dose-related reversal of acute rejection by aerosolized cyclosporine. Am J Respir Crit Care Med 1997; 155: 1690.
25. O'Riordan TG, Duncan SR, Burckart GJ, Griffith BP, Smaldone GC. Production of an aerosol of cyclosporine: a prelude to clinical studies. J Aerosol Med 1992; 5: 171.
26. Zeevi A, Kaufman C, Duquesnoy R. Clinical relevance of lymphocyte analysis in cardiac and pulmonary transplantation. In: Rose ML Yacoub MM, eds. Immunology of heart and lung transplantation. London: Edward Arnold Publishers, 1993: 188.
27. Zeevi A, Dauber JH, Yousem SA. Immunologic alterations in chronic lung rejection. In: Shenib H, ed. Immunology of the lung allograft. Montreal: Lands Medical Publishers, 1995.
28. Wang S, Morel P, Wang Q, Jordan ML, Simmons RL, Tweardy DJ. A dual mechanism of immunosuppression by FK506 differential suppression of IL-4 and IL-10 levels in T helper 2 cells. Transplantation 1993; 56: 978.
29. Wang SC, Zeevi A, Jordan MA, Simmons RL, Tweardy DJ. FK506, rapamycin and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T helper 2 cell line. Transplant Proc 1991; 23: 2920.
30. Xu GP, Sharma VK, Li B, et al. Intragraft expression of IL-10 messenger RNA: a novel correlate of renal allograft rejection. Kidney Int 1995; 40: 1504.
31. Azzawi M, Hasleton PS, Grant SC, Stewart JP, Hutchinson IV. Interleukin-10 in human heart transplantation: an in situ hybridization study. J Heart Lung Transplant 1994; 14: 519.
32. Sharma VK, Li B, Khanna A, Sehajpal PK, Suthanthiran M. Which way for drug-mediated immunosuppression? Curr Opin Immunol 1994; 6: 784.
33. Khanna A, Li B, Stenzel KM, Suthanthiran M. Regulation of new DNA synthesis in mammalian cells by cyclosporine: demonstration of a transforming growth factor β-dependent mechanisms of inhibition of cell growth. Transplantation 1994; 57: 577.
34. Robens AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 1993; 8: 1.